IL200905A0 - Compounds and compositions comprising the same for use in treating hepatitis c - Google Patents

Compounds and compositions comprising the same for use in treating hepatitis c

Info

Publication number
IL200905A0
IL200905A0 IL200905A IL20090509A IL200905A0 IL 200905 A0 IL200905 A0 IL 200905A0 IL 200905 A IL200905 A IL 200905A IL 20090509 A IL20090509 A IL 20090509A IL 200905 A0 IL200905 A0 IL 200905A0
Authority
IL
Israel
Prior art keywords
compositions
compounds
same
treating hepatitis
hepatitis
Prior art date
Application number
IL200905A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL200905A0 publication Critical patent/IL200905A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL200905A 2007-03-14 2009-09-13 Compounds and compositions comprising the same for use in treating hepatitis c IL200905A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89488707P 2007-03-14 2007-03-14
US98947407P 2007-11-21 2007-11-21
PCT/US2008/055893 WO2008112473A1 (en) 2007-03-14 2008-03-05 Compounds for the treatment of hepatitis c

Publications (1)

Publication Number Publication Date
IL200905A0 true IL200905A0 (en) 2010-05-17

Family

ID=39477552

Family Applications (1)

Application Number Title Priority Date Filing Date
IL200905A IL200905A0 (en) 2007-03-14 2009-09-13 Compounds and compositions comprising the same for use in treating hepatitis c

Country Status (19)

Country Link
US (1) US7547690B2 (esLanguage)
EP (1) EP2118109B1 (esLanguage)
JP (1) JP5232178B2 (esLanguage)
KR (1) KR20100015304A (esLanguage)
CN (1) CN101657455B (esLanguage)
AR (1) AR065772A1 (esLanguage)
AU (1) AU2008226639B2 (esLanguage)
BR (1) BRPI0808763A2 (esLanguage)
CA (1) CA2681093A1 (esLanguage)
CL (1) CL2008000751A1 (esLanguage)
CO (1) CO6180426A2 (esLanguage)
EA (1) EA016614B1 (esLanguage)
IL (1) IL200905A0 (esLanguage)
MX (1) MX2009009473A (esLanguage)
NZ (1) NZ579342A (esLanguage)
PE (1) PE20090648A1 (esLanguage)
TW (1) TW200848058A (esLanguage)
WO (1) WO2008112473A1 (esLanguage)
ZA (1) ZA200906129B (esLanguage)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049622A1 (ja) * 2003-11-19 2005-06-02 Japan Tobacco Inc. ５－５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途
US20070049593A1 (en) * 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
KR20100108341A (ko) * 2007-11-20 2010-10-06 브리스톨-마이어스 스큅 컴퍼니 시클로프로필 융합된 인돌로벤즈아제핀 ｈｃｖ ｎｓ5ｂ 억제제
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
CA2710644C (en) 2007-12-24 2016-03-29 Tibotec Pharmaceuticals Macrocyclic indoles as hepatitis c virus inhibitors
KR20100134699A (ko) * 2008-03-27 2010-12-23 브리스톨-마이어스 스큅 컴퍼니 디옥솔란 및 디옥솔라논 융합된 인돌로벤자디아제핀 ｈｃｖ ｎｓ5ｂ 억제제
KR20100139082A (ko) * 2008-03-27 2010-12-31 브리스톨-마이어스 스큅 컴퍼니 Ｃ형 간염 치료를 위한 화합물
WO2009120733A1 (en) * 2008-03-27 2009-10-01 Bristol-Myers Squibb Company Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
EP2509982A1 (en) 2009-12-07 2012-10-17 Targacept, Inc. 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands
US8716275B2 (en) * 2011-10-20 2014-05-06 Bristol-Myers Squibb Company Compound for the treatment of hepatitis C
WO2014011863A1 (en) * 2012-07-12 2014-01-16 Targacept, Inc. Method of treatment with 3-cyclopropylcarbonyl-3,6-diazabicyclo[3.1.1]heptane
CA2879398A1 (en) * 2012-07-18 2014-01-23 Bristol-Myers Squibb Holdings Ireland Novel methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3-methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide
MX2018011214A (es) 2016-03-15 2019-03-28 Bayer Cropscience Ag Sulfonamidas sustituidas para controlar plagas animales.
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
CN110028510A (zh) * 2019-05-22 2019-07-19 南京合巨药业有限公司 一种3-甲基-3,6-二氮杂-双环[3,1,1]庚烷二盐酸盐的制备方法
EP4055010A1 (de) 2019-11-07 2022-09-14 Bayer Aktiengesellschaft Substituierte sulfonylamide zur bekämpfung tierischer schädlinge
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20090250T1 (hr) 2004-02-24 2009-06-30 Japan Tobacco Kondenzirani heterociklički spojevi i njihova upotreba kao inhibitora hcv polimeraze
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
RU2007119562A (ru) 2004-10-26 2008-12-10 Институто Ди Ричерке Ди Биолоджиа Молеколаре П Анджелетти Спа (It) Тетрациклические производные индолов в качестве противовирусных агентов
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) * 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) * 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) * 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521442B2 (en) * 2006-05-25 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CN101490054B (zh) * 2006-05-25 2012-05-16 百时美施贵宝公司 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
US7452876B2 (en) * 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors

Also Published As

Publication number Publication date
CN101657455A (zh) 2010-02-24
CA2681093A1 (en) 2008-09-18
AU2008226639B2 (en) 2012-07-19
US20080227769A1 (en) 2008-09-18
PE20090648A1 (es) 2009-05-29
US7547690B2 (en) 2009-06-16
WO2008112473A1 (en) 2008-09-18
MX2009009473A (es) 2009-09-15
AU2008226639A1 (en) 2008-09-18
EP2118109A1 (en) 2009-11-18
ZA200906129B (en) 2010-11-24
CN101657455B (zh) 2013-02-06
TW200848058A (en) 2008-12-16
CO6180426A2 (es) 2010-07-19
EA200901241A1 (ru) 2010-02-26
CL2008000751A1 (es) 2008-07-25
EP2118109B1 (en) 2014-11-26
JP5232178B2 (ja) 2013-07-10
KR20100015304A (ko) 2010-02-12
EA016614B1 (ru) 2012-06-29
JP2010521476A (ja) 2010-06-24
BRPI0808763A2 (pt) 2014-09-16
AR065772A1 (es) 2009-07-01
NZ579342A (en) 2011-07-29

Similar Documents

Publication Publication Date Title
IL200905A0 (en) Compounds and compositions comprising the same for use in treating hepatitis c
IL195198A0 (en) Biphenyl derivatives and their use in treating hepatitis c
PL2653873T1 (pl) Kompozycje i zastosowania do leczenia stwardnienia rozsianego
AP2965A (en) Therapeutic compositions and the use thereof
IL198248A0 (en) Hepatitis c virus inhibitors and compositions comprising the same
AP2490A (en) Therapeutic compositions and the use thereof
IL213365A (en) Imidazopyrazine and their pharmaceutical preparations
IL197804A0 (en) Compositions for the trearment of hepatitis c and methods for using compositions for the treatment of hepatitis c
PL2120999T3 (pl) KOMPOZYCJE FARMACEUTYCZNE ZAWIERAJĄCE ANTAGONISTÓW AKTYWINY-ActRIIA I ICH ZASTOSOWANIE W ZAPOBIEGANIU LUB LECZENIU SZPICZAKA MNOGIEGO
SI2079485T1 (sl) Fenilpropionamidne spojine in njihova uporaba
EP2130843A4 (en) POLYMERIZABLE COMPOUNDS AND POLYMERIZABLE COMPOSITIONS
EP2271218A4 (en) USE AND COMPOSITION FOR THE TREATMENT OF DEMENTIA
IL202425A0 (en) Tri-aryl compounds and compositions comprising the same
IL225911A (en) Citrulline preparations for use in the treatment of asthma
IL210226A (en) Azul compound and pharmaceutical preparations containing them
EP2182980A4 (en) METHOD AND COMPOSITIONS FOR INCREASED ALPHA IDURONIDASE ACTIVITY IN THE CNS
EP2307052A4 (en) ANTI-BETA-2-MICROGLOBULIN AGENTS AND THEIR USE
IL207639A0 (en) Pyrrolopyrimidinecarboxamide compounds, compositions comprising the same and uses thereof
EP2196211A4 (en) APOLACTOFERRIN COMPOSITIONS AND METHOD FOR THEIR USE IN THE TREATMENT OF VIRAL HEPATITIS C
GB0903427D0 (en) Fluid compositions and methods for the use thereof
GB0714500D0 (en) composition and treatment
GB2461611B (en) Composition and use thereof
GB0526292D0 (en) A composition for use in the treatment of a surface
ZA200809797B (en) Biphenyl derivatives and their use in treating hepatitis C
ZA201000469B (en) Therapeutic compositions and the use thereof